Abstract-Closed-loop control of anesthesia is expected to decrease drug dosage and wake up time while increasing patient safety and decreasing the work load of the anesthesiologist. The potential of closed-loop control in anesthesia has been demonstrated in several clinical studies. One of the challenges in the development of a closed-loop system that can be widely accepted by clinicians and regulatory authorities is the effect of interpatient variability in drug sensitivity. This system uncertainty may lead to unacceptable performance, or even instability of the closed-loop system for some individuals. The development of reliable models of the effect of anesthetic drugs and characterization of the uncertainty is, therefore, an important step in the development of a closed-loop system. Model identification from clinical data is challenging due to limited excitation and the lack of validation data. In this paper, approximate models are validated for controller design by evaluating the predictive accuracy of the closed-loop behavior. A set of 47 validated models that describe the interpatient variability in the response to propofol in children is presented. This model set can be used for robust linear controller design provided that the experimental conditions are similar to the conditions during data collection.
propofol requires continuous monitoring of the hypnotic state by the anesthesiologist, and adjusting of drug dosing to the individual need.
Traditionally, the propofol infusion rate is controlled manually by the anesthesiologist. Computer aided open-loop delivery systems known as target controlled infusion (TCI) systems are commercially available for adult patients. In this open-loop control setting, the target concentration needs to be adjusted by the anesthesiologist to maintain adequate anesthesia, due to widely varying individual patient responses to propofol. The use of TCI systems in children is limited due to the large interpatient variability of PKPD behavior in children and the debated validity of pediatric PKPD models [2] . Closed-loop control of propofol infusion using feedback from a measure of the depth of hypnosis (DOH) can reduce the effect of interpatient variability and improve control of DOH [3] . At the same time, this variability introduces a challenge for closed-loop control in anesthesia [4] . Uncertainty limits the achievable control bandwidth and characterization of the uncertainty is required to ensure stability and performance of the closed-loop system [4] .
The goal of this study is to identify models of the effect of propofol on the DOH in children that describe the interpatient variability in children age 6-16 years, for the purpose of robust linear controller design. The WAV CNS index 3 (NeuroSENSE monitor, NeuroWave Systems Inc. Cleveland Heights, USA) is used as measure of the clinical effect. The NeuroSENSE monitor was developed specifically for use in closed-loop control. It does not introduce a delay and its dynamic behavior is consistent and well characterized [5] , [6] .
Model identification from clinical data from propofol anesthesia introduces fundamental challenges [7] . Propofol infusion profiles in clinical practice provide limited excitation, propofol is often used in combination with fast acting opioids like remifentanil that have a synergistic effect, and the response to propofol infusion is nonlinear. Nonlinear dynamic model structures are generally not identifiable from the clinical data. If the data are not sufficiently rich, a good fit of the model with the data is insufficient for model validation. In this paper, simple models based on a linear approximation [8] are identified from clinical data from open-and closed-loop induction of anesthesia. In addition to evaluating the model fit, the models are validated for the design of linear controllers by comparing the predicted closed-loop behavior to measured responses under the same controller.
PKPD models that are traditionally used to describe the effect of propofol contain a third-order linear PK model, and a PD model consisting of a first-order linear transfer function and an output nonlinearity (a Wiener model) [2] . Simplifications in the model structure have been proposed to improve identifiability from clinical data: PKPD model structures with some parameters fixed [2] , [8] , [9] , first-order plus time-delay (FOPTD) models with an output nonlinearity [7] , [10] , piecewise linear models [11] , and a simplified model for the effect of both propofol and remifentanil including an output nonlinearity [12] . Identifiability of these proposed structures has not been evaluated. Normally, only one set of clinical data is available per subject and identified models are often validated based on the model fit with the identification data set [7] , [10] [11] [12] . Due to the limited excitation in the clinical data, the predictive capacity of these models validated based on the identification data is difficult to evaluate. Ten and fifteen minute ahead predictions were considered by [9] to evaluate the model quality for its intended use, i.e., real-time prediction of individual responses.
The models identified in this study are developed for the design of robust linear controllers. It is well known that simple linear models are often sufficient to achieve good control performance, even for systems with nonlinear behavior [13] . Such a linear approximate model depends on the experimental conditions [14] , and can be considered a good model for a system controlled by a specific controller if the distance between the predicted and achieved closed-loop system is small for that specific controller [15] , [16] . Validation of the model set identified in this study, therefore, includes evaluation of the predicted closed-loop response and a comparison of this response to clinical closed-loop data. Two model structures (PKPD and FOPTD) are considered. It is shown that the predicted closed-loop performance is comparable for these structures. The parameters for both model sets are given for 47 subjects. Both validated model sets can be used for controller design, provided the experimental conditions are similar to the conditions during data collection [16] .
The PKPD and FOPTD model structures are described in Section II. Section III discusses the clinical data that were available for the identification and highlights the characteristics of this data and their effect on model identification. Section IV describes the identification procedure and Section V summarizes the results. Model validation is discussed in Section VI. Concluding remarks are given in Section VII.
II. MODELING THE EFFECT OF PROPOFOL

A. PKPD Model Structure
The effect of propofol on the DOH is traditionally modeled using compartmental PKPD models [4] , whose model structure is shown in Fig. 1(a) . The PK model relates the drug infusion rate u(t) to the plasma concentration C p (t), C p (s) = PK(s)u(s), where PK(s) can be written as
using the central compartment volume V 1 and the PK distribution time constants π, α, β, k 21 , and k 31 . The PD model consists of a FOPTD transfer function, describing the dynamics between C p (t) and the concentration of propofol at the effect site C e (t), and the nonlinear Hill function defined as
describing the relation between C e (t) and the clinical effect E(t). EC 50 is the effect-site concentration at which half of the maximum effect is achieved and γ determines the nonlinearity.
In this study, the PK model is fixed to reduce the number of variables to identify. Only the PD parameters are identified, following the approach in [8] . The Paedfusor PK model [17] is used to predict C p (t). The parameters of the PD model, 50 , and γ, are identified from data.
B. FOPTD Model Structure
FOPTD models are commonly used for controller design and their use to describe the effect of propofol on the DOH has been proposed [7] , [10] . The FOPTD model directly relates the infusion rate to the clinical effect, as shown in Fig. 1(b) . In this model structure, the nonlinear Hill function is defined as
where E LT I (t) is the effect as predicted by the LTI block, see Fig. 1(b) . The system gain is modeled using E 50 and the nonlinearity is parameterized by γ. The unknown parameters E 0 , k, T d , E 50 , and γ are identified. Note that the number of unknown parameters in this FOPTD structure is the same as the number of unknown parameters in the PKPD structure where the PK model is fixed.
III. CLINICAL DATA
Data from both open-loop and closed-loop controlled anesthesia were available for this identification study. 
A. Open-Loop Data
Following approval from the institutional research ethics board (REB), data were analyzed for 30 children undergoing elective general surgery using total intravenous anesthesia. Fig. 2 (a) shows the data collection setup. Propofol and remifentanil were administered as an initial bolus followed by a continuous infusion, manually controlled by the anesthesiologist.
Propofol infusion is represented by u(t). The clinical effect E(t)
is affected by the opioid infusion due to the synergistic effect of remifentanil. The clinical effect E(t) is measured as the WAV CNS index [6] . The measured DOH is affected by stimulation from the procedure d(t) and measurement noise n(t). The monitor dynamics, relating the clinical effect E(t) to the measured WAV CNS index, are determined by the trending filter [6] , and correspond to G M (s) = 1/(8s + 1) 2 for a 30 s filter [8] . Propofol infusion rates were recorded manually. The WAV CNS index was recorded every second throughout the case.
B. Closed-Loop Data
Propofol infusion rates and recordings of the WAV CNS index were available from a clinical pilot study of closed-loop control of propofol anesthesia in children [1] . Following REB approval, and informed consent/assent, 69 children age 6-16 years (11±3 years, 34 male, 43±15 kg, 150±17 cm) ASA I-II, 4 requiring anesthesia for elective upper and/or lower gastrointestinal endoscopic investigations were enrolled for this study. Fig. 2 (b) shows the setup for closed-loop control of DOH. The setpoint is defined by the anesthesiologist and the propofol infusion rate is calculated by the controller. The closed-loop system uses feedback from the NeuroSENSE DOH monitor. Propofol is delivered by an Alaris TIVA infusion pump (CareFusion, San Diego, CA, USA) connected to an intravenous line. In addition to the robust PID controller, the control system contains necessary safety layers and alarms. During the cases, both information from the control system and the physiological monitors is recorded every second. Remifentanil was administered 4 American Society of Anesthesiologists physical status classification system. ASA I: normal healthy patient, ASA II: patient with mild systemic disease. figure) and corresponding propofol infusion rates (bottom figure) collected during two typical cases. Solid line: in this case the propofol infusion was controlled manually by the anesthesiologist. An initial bolus was followed by a continuous infusion. A bolus was given in response to stimulation after approx. 12 min. Drug infusion was stopped after approx. 15 min. Dashed line: in this case the propofol infusion rate was closed-loop controlled. Drug infusion was stopped after approx. 35 min.
as a bolus (0.5 μg/kg) prior to propofol administration followed by continuous infusion (0.03 μg/kg/min).
Closed-loop data were recorded for 23 cases using an initial robust PID controller design [1] . The observed responses in these 23 cases indicated sufficient robustness and the controller was retuned to improve the speed of induction of anesthesia and the response to stimulation (PKPD models identified from data of these 23 cases were used for the controller redesign). This retuned system was evaluated in 46 additional cases. Consequently, data from a total of 69 cases of closed-loop control of propofol anesthesia were available for system identification.
C. Characteristics of Clinical Data From Propofol Anesthesia
Clinical data collected during typical cases of both openloop and closed-loop controlled anesthesia are shown in Fig. 3 . The effect of propofol depends on the remifentanil infusion due to the synergistic effect of these drugs. This synergy is not taken into account and the identified models will be affected by the remifentanil infusion. Consequently, the models can only be validated for similar experimental settings and comparable remifentanil administration.
As indicated in Fig. 2 , the clinical data contain measurement noise n(t) as well as disturbances due to stimulation from the procedure d(t). The measurement noise is assumed to be zero mean. Nociceptive stimulation caused by the procedure decreases the clinical effect and cannot be assumed to be zero mean. The data from the open-loop controlled case show an example of the effect of stimulation on the measured DOH after 12 min. The anesthesiologist gave a bolus of propofol after noticing the response to stimulation. The closed-loop controlled case shows several responses to stimulation, at the start of the case (after about 4 min) and during maintenance of anesthesia (around 15 and 23 min). Surgical stimulation cannot be measured, and because the associated disturbances are not zero mean, the effect of stimulation will introduce a bias in model identification.
During induction of anesthesia, nociceptive stimulation is generally limited, and data from induction of anesthesia can be used for the identification to limit the effect of disturbances on the identified model [8] , [10] . However, initial scope insertion during endoscopic procedures and the insertion of airway devices during general surgery can cause nociceptive stimulation. Cases that show a significant reaction during induction of anesthesia need to be discarded to limit the bias in the identified model.
Nonlinear model structures including the structures shown in Fig. 1 are generally not identifiable from clinical data [10] , [12] . During induction of anesthesia, the WAV CNS changes from ≈90 (awake) to 50 (adequate anesthesia), corresponding to a step response. The effect of the nonlinearity γ cannot be distinguished from the dynamic parameters T d and k d (or k) due to the limited excitation in the step response. However, a linear approximation of the system identified from the step response can provide an adequate approximate model for controller design [13] .
IV. MODEL IDENTIFICATION FROM CLINICAL DATA
A. Data Selection
The quality of models identified from data depends strongly on the quality of that data. Therefore, the clinical data were inspected visually and manually selected before identification. To achieve this, we took clear signs of response to stimulation in the measured WAV CNS into account as well as additional observations and information collected in the operation room.
1) Open-Loop Data:
The first 8 min after the start of propofol infusion were used for the model identification. Data were incomplete for six cases. Induction of anesthesia required volatile anesthetics in two cases. Five cases were discarded due to corrupted data or insufficient data quality. Three cases were discarded because they showed a strong reaction to stimulation during the induction of anesthesia. The recorded data for the remaining 14 cases are shown in Fig. 4 . Data interpolation at a stable WAV CNS index was performed in four cases, where 5 s (1 case), 10 s (2 cases), and 40 s (1 case) of data were missing. The recordings in Fig. 4 clearly show the interpatient variability observed in response to propofol anesthesia in children.
2) Closed-Loop Data: The speed of induction of anesthesia was slower in the closed-loop study than in the open-loop study, therefore, the first 10 min after the start of propofol infusion was used for the identification. Recordings of 33 out of the original 69 cases show a strong reaction to stimulation during the first 10 min after the start of propofol infusion and were discarded after visual inspection. Data from the remaining 36 subjects, shown in Fig. 5 , were used for the model identification.
Note that some reaction to stimulation due to insertion of airway devices or scope insertion during endoscopic investigations is common. The large number of cases discarded to avoid bias in the identified model as a result of stimulation is related to the low dose of remifentanil administered during these procedures. It is not a result of the use of closed-loop control.
B. Identification of the Model Parameters
In a two-step identification approach, a linear approximation is initially identified. This linear approximation of the step response is expected to provide an adequate approximation for controller design [13] . In a second step, the model fit is improved through optimization of the nonlinearity γ. In the first step, identifying the linearized model, the monitor dynamics and the PD model are commutative and the infusion profile or the plasma concentration can be filtered by G M to account for these dynamics [8] . The nonlinearity is expected to be underestimated because the nonlinear behavior is approximated by a linear model in the first step. The tradeoff between the dynamic parameters T d and k d (or k) and the nonlinearity γ is, therefore, expected to tend toward larger time delays, slower dynamics, and smaller values for γ.
For each set of open-and closed-loop data, E 0 is estimated as the average effect measured during the first 50 s after the start of propofol infusion (no response is expected during this period). In some data sets, the WAV CNS index increased at the start of the case, possibly related to pain on injection of propofol. This increase can lead to overestimation of T d . Therefore, the time delay is limited to T d < 120s. The models are discretized using the Euler method.
The FOPTD models are identified as follows. The infusion profile is filtered by the dynamics of the monitor G M . A linearization of the model is identified using the output-error method [18] . In a second optimization step, γ is identified.
Identification of the PKPD models requires calculation of the plasma concentrations C p (t) corresponding to the infusion profile u(t). The Paedfusor population PK model [17] is used to predict C p (t). The C p (t) profiles are filtered by G M . In the first optimization step, a linearization of the PD model is identified using the output-error method. In a second step, the model fit is improved by identifying γ in (2) .
Remark: Direct identification from closed-loop data using the output-error approach is known to result in biased models. When the data are collected in closed-loop, the input to the system is correlated to the noise. In that case, direct identification using the system input (controller output) and output (measured WAV CNS ) is unbiased with respect to noise, only if both the system model and the noise model are in the model set [19] . Identification of the noise model or the use of indirect identification could be considered to provide a consistent estimate. For the identification of models with a fixed structure, i.e., the PKPD models or FOPTD models considered in this study, "tailor-made" parameterizations could be used. However, when undermodeling of the plant is present, these methods will also introduce bias.
Direct identification and indirect identification differ by the choice of noise model [19] . If there is no undermodeling of the plant, an unbiased plant model can be obtained when the structure of the noise model is chosen correctly. In case of undermodeling of the plant, there will be a bias for all methods. The frequency weighting of this bias depends on the identification method and corresponding noise model. If the SNR ratio is large or if the feedback noise contribution to the input of the identified model is small, the bias due to noise in the direct approach will be small [19] .
When identifying a linear approximation of the response to propofol infusion during induction of anesthesia, a nonlinear plant is approximated by a linear model and undermodeling will be present. All closed-loop identification methods will, therefore, introduce bias [19] . Direct identification using the outputerror approach was chosen because the optimization problem is relatively simple and the bias due to noise is expected to be small. The high-frequency noise is low-pass filtered by G M . In the PKPD model structure, additional low-pass filtering by the PK model removes most of the noise contribution to the input of the identified PD model. Advantages of alternative closedloop identification methods (different bias weighting) are not expected to outweigh the cost of increased complexity of the optimization problem, the increased number of parameters to be identified and the increased risk of finding local minima. Validation of the predicted closed-loop response supports this choice.
V. RESULTS
A. Open-Loop Data
For each of the 14 open-loop cases, a PKPD model and a FOPTD model were identified. For 8 out of the 14 cases, the FOPTD models achieve a better fit with the data than the PKPD models. The average of the rms residual errors between the data and the predicted model output were 3.61(±0.85) (mean rms(±std)) for the FOPTD models and 3.79(±0.85) for the PKPD models.
B. Closed-Loop Data
For each of the 36 closed-loop cases, a FOPTD model and a PKPD model were identified. The FOPTD models achieve a better fit than the PKPD models for 25 out of the 36 cases. The average of the rms residual errors (mean rms(±std)) between the data and the predicted model output was 3.55(±0.82) for the FOPTD models and 3.68(±0.79) for the PKPD models.
For both the open-and closed-loop data, the FOPTD models achieve a better fit on average than the PKPD models. This confirms the results of [10] . Note that the differences are not clinically relevant.
VI. MODEL VALIDATION
A. Comparing the Model Prediction to the Identification Data
The predicted output for each model is compared to the identification data and the fit is inspected visually. The fit was deemed sufficient for both the PKPD and the FOPTD models for 49 out of the 50 subjects and these 49 models are validated based on the fit with the identification. Examples of a sufficient fit are shown in Figs. 6 and 7. Fig. 8 shows the fit obtained for the 50th subject. The rms residual error for this subject is 5.25 for the FOPTD model and 5.08 for the PKPD model. After visual inspection, it is concluded neither the FOPTD nor the PKPD model captures the dynamics of the response. The data show response to stimulation after ≈5 min. The models are biased because of this disturbance. This case accentuates the variability in response to stimulation and the need for visual inspection of both the data and the model predictions.
B. Closed-Loop Response
Due to the limited excitation in clinical data and the resulting identifiability issues, different models with the same structure can provide an adequate fit with the data. Model validation based on rms errors and visual inspection of the fit is, therefore, insufficient. To overcome this limitation, the models identified in this study are validated for robust linear controller design. A good model for a system controlled by a specific controller achieves a small distance between the predicted and achieved closed-loop system for that controller [15] , [16] . A minimal requirement for a validated model is, therefore, that the model achieves a small distance between the predicted and measured responses for the controller that was clinically evaluated. In the following, the models are therefore validated based on the predicted closed-loop performance of the models controlled by the redesigned PID controller as described in Section III-B. Fig. 9 shows the simulated closed-loop response of the complete set of 50 identified models controlled by the clinically evaluated PID controller. The measured closed-loop responses under the same controller are shown for comparison. The induction time 5 for the PKPD and FOPTD models are similar (mean (±std) 3.6 min (±42s) and 3.7 min (±44 s), respectively). The overshoot upon induction is 8(±3) for the PKPD models and 9(±4) for the FOPTD models. The PKPD models show less variability in the predicted settling time 6 ; 13 min (±3.4 min) for the PKPD models, 13.4 min (±5.3 min) for the FOPTD models. The response of the FOPTD models that contain an integrator is not realistic (constant WAV CNS ≈ 30 and zero infusion).
The responses of the PKPD models show three distinct outliers, highlighted in Fig. 9 . One of these outliers corresponds to the models for the subject shown in Fig. 8 , for which the model fit was insufficient. The simulated response of the two other outliers was compared to the observed response. The simulated response for the case shown in Fig. 10 corresponds to the measured response for up to 10 min, but deviates after these 10 min. The oscillation in the simulated system indicates smaller robustness margins than observed in practice. Similar dynamics were observed for the third outlier. The use of these three models in controller design would lead to overly conservative controllers, the three outliers highlighted in Fig. 9 are, therefore, considered invalid for controller design.
Comparison of the simulated closed-loop response of the remaining 47 models to the measured responses under the same controller shows that the model set captures the observed interpatient variability and provides a good description of the system's response to induction of anesthesia. Note that the measured data are affected by nociceptive stimulation and that the setpoint for the controller was changed to 60 in some cases after 10 or more minutes (the anesthesiologist considered this lighter anesthetic state sufficient in these cases).
The identified models are based on a linear approximation. The interpatient variability is, therefore, largely described by the linear dynamics of the models. This variability in the linear dynamics can be used for the design of robust linear controllers. The model sets of 47 models are validated for the design of robust linear controllers for induction and maintenance of anesthesia, provided that the experimental conditions are similar to the experimental conditions during data collection. Fig. 11 shows the Bode diagrams for both the PKPD and the FOPTD models. The models are normalized with respect to the subject's weight and the model gains are linearized for the induction of anesthesia. 7 At high frequencies, the roll-off of the PKPD models is higher than the roll-off of the FOPTD models, rad/s). The variability is also comparable in this bandwidth. The closed-loop behavior of the FOPTD and PKPD models is, therefore, similar under the same controller. A complete list of the identified parameters for both the PKPD and the FOPTD structure is given in Table I . The FOPTD model set shows more variability although the difference is marginal. The time response of the PKPD models is more realistic than the time response of the FOPTD models. Both model sets are appropriate for the design of linear robust controllers. Depending on the controller design method and the requirements imposed by that method, either the FOPTD or the PKPD model set can be favored. For these models based on a linear approximation:
C. Model Sets for Robust Linear Controller Design
1) The model validity is limited to experimental conditions where the linearization is expected to provide a good approximation of the system behavior. If the experimental settings change significantly, for example, significant changes in speed of induction or in opioid infusion, the models may not be adequate for controller design. 2) The identified PD parameters in the PKPD structure have limited physiological meaning.
3) The identified parameters in the FOPTD models have limited physiological meaning. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] are identified from open-loop data. Models for subject 15-47 are identified from closed-loop data. The kd values that are adjusted because of negative discrete poles are highlighted. Since the same data set is used to identify the PKPD models and the FOPTD models, E0 has the same value for both model structures. The presented PD parameters for the PKPD models are identified based on plasma concentration predictions using the Paedfusor model [17] and should be used in combination with this PK model.
4)
The time delay in the FOPTD models represents the phase shift between the propofol infusion and the observed clinical effect and does not provide a realistic estimate of the time delay observed clinically, for example, during the maintenance of anesthesia.
VII. CONCLUSION
This paper presents a set of models that describe the effect of propofol infusion in children age 6-16 years, identified from clinical data of induction of anesthesia. Identification of nonlinear models from clinical data is challenging due to limited excitation in the signals. Furthermore, when the data is not sufficiently exciting, a good fit of the model with the identification data is not sufficient for model validation. To overcome these identifiability issues, control relevant approximate models are identified and validated for controller design by evaluating the predictive accuracy of the closed-loop response under a known controller. A PKPD structure with a time delay and output nonlinearity and a FOPTD structure with an output nonlinearity are considered. The presented models are validated for the design of robust linear controllers.
PKPD and FOPTD models are presented for 47 individuals. The FOPTD models obtain a better fit with the data. The predicted closed-loop behaviors are similar for both model sets under the same controller. As a consequence of the identifiability issues, the identified parameters have limited physiological meaning. Care should be taken in the interpretation of simulation results in experimental settings that are significantly different from the conditions during data collection. Both model sets provide a realistic indication of the interpatient variability in response to propofol infusion.
